Hepion Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

HEPA Stock

USD 0.63 0.02 3.28%

Hepion Pharmaceuticals financial indicator trend analysis is much more than just examining Hepion Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Hepion Pharmaceuticals is a good investment. Please check the relationship between Hepion Pharmaceuticals Ev To Free Cash Flow and its Free Cash Flow Yield accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Hepion Pharmaceuticals Ev To Free Cash Flow account and Free Cash Flow Yield. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Hepion Pharmaceuticals' Ev To Free Cash Flow and Free Cash Flow Yield is -0.39. Overlapping area represents the amount of variation of Ev To Free Cash Flow that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Hepion Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Hepion Pharmaceuticals' Ev To Free Cash Flow and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ev To Free Cash Flow of Hepion Pharmaceuticals are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Ev To Free Cash Flow i.e., Hepion Pharmaceuticals' Ev To Free Cash Flow and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.39

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Hepion Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Hepion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.At present, Hepion Pharmaceuticals' Enterprise Value Over EBITDA is projected to increase based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.04, whereas Selling General Administrative is forecasted to decline to about 6.5 M.

Hepion Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Non Currrent Assets Other	Property Plant And Equipment Gross	Property Plant And Equipment Net	Non Current Assets Total	Other Assets	Capital Surpluse	Other Current Assets	Property Plant Equipment	Short Long Term Debt Total	Other Liab
Total Assets		0.84	0.86	0.98	-0.99	-0.58	0.56	1.0	1.0	0.59	0.64	0.06	0.75	0.61	1.0	0.7	0.9	0.58	0.52	0.59	0.12	0.7	0.92	0.45	0.11	-0.7
Other Current Liab	0.84		0.87	0.81	-0.84	-0.7	0.44	0.84	0.84	0.75	0.83	0.09	0.8	0.64	0.86	0.67	0.86	0.64	0.22	0.34	-0.15	0.77	0.95	0.09	-0.04	-0.67
Total Current Liabilities	0.86	0.87		0.79	-0.83	-0.76	0.81	0.84	0.84	0.75	0.73	0.33	0.83	0.85	0.85	0.65	0.86	0.54	0.34	0.58	0.21	0.81	0.88	0.18	0.11	-0.73
Total Stockholder Equity	0.98	0.81	0.79		-0.99	-0.46	0.47	0.99	0.98	0.46	0.55	-0.07	0.65	0.5	0.98	0.7	0.86	0.52	0.51	0.57	0.08	0.59	0.89	0.48	0.07	-0.63
Net Debt	-0.99	-0.84	-0.83	-0.99		0.53	-0.53	-1.0	-1.0	-0.55	-0.61	-0.01	-0.7	-0.57	-1.0	-0.72	-0.88	-0.54	-0.48	-0.55	-0.06	-0.65	-0.92	-0.43	-0.05	0.65
Retained Earnings	-0.58	-0.7	-0.76	-0.46	0.53		-0.56	-0.56	-0.57	-0.84	-0.9	-0.34	-0.97	-0.7	-0.57	-0.19	-0.8	-0.76	-0.43	-0.27	-0.09	-0.98	-0.7	-0.17	-0.18	0.86
Accounts Payable	0.56	0.44	0.81	0.47	-0.53	-0.56		0.53	0.53	0.56	0.42	0.52	0.56	0.81	0.54	0.47	0.53	0.26	0.33	0.55	0.46	0.58	0.51	0.18	0.07	-0.45
Cash	1.0	0.84	0.84	0.99	-1.0	-0.56	0.53		1.0	0.58	0.65	0.02	0.73	0.58	1.0	0.7	0.88	0.57	0.5	0.54	0.06	0.69	0.93	0.43	0.06	-0.67
Cash And Short Term Investments	1.0	0.84	0.84	0.98	-1.0	-0.57	0.53	1.0		0.59	0.65	0.02	0.74	0.58	1.0	0.69	0.88	0.57	0.5	0.54	0.06	0.69	0.93	0.43	0.06	-0.67
Common Stock Total Equity	0.59	0.75	0.75	0.46	-0.55	-0.84	0.56	0.58	0.59		0.85	0.44	0.84	0.74	0.59	0.52	0.63	0.54	0.11	0.17	-0.05	0.85	0.69	-0.13	0.13	-0.6
Common Stock Shares Outstanding	0.64	0.83	0.73	0.55	-0.61	-0.9	0.42	0.65	0.65	0.85		0.12	0.92	0.57	0.66	0.28	0.77	0.72	0.23	0.03	-0.29	0.94	0.83	-0.01	-0.14	-0.69
Non Current Liabilities Total	0.06	0.09	0.33	-0.07	-0.01	-0.34	0.52	0.02	0.02	0.44	0.12		0.25	0.77	0.02	0.21	0.12	0.16	0.11	0.38	0.5	0.27	-0.01	-0.02	0.35	-0.25
Other Stockholder Equity	0.75	0.8	0.83	0.65	-0.7	-0.97	0.56	0.73	0.74	0.84	0.92	0.25		0.7	0.74	0.33	0.89	0.79	0.5	0.36	0.08	0.99	0.82	0.27	0.17	-0.9
Total Liab	0.61	0.64	0.85	0.5	-0.57	-0.7	0.81	0.58	0.58	0.74	0.57	0.77	0.7		0.58	0.55	0.65	0.46	0.3	0.61	0.43	0.7	0.59	0.12	0.28	-0.64
Total Current Assets	1.0	0.86	0.85	0.98	-1.0	-0.57	0.54	1.0	1.0	0.59	0.66	0.02	0.74	0.58		0.69	0.89	0.57	0.49	0.53	0.05	0.7	0.94	0.42	0.05	-0.67
Common Stock	0.7	0.67	0.65	0.7	-0.72	-0.19	0.47	0.7	0.69	0.52	0.28	0.21	0.33	0.55	0.69		0.45	0.11	0.05	0.49	0.12	0.28	0.63	0.05	0.13	-0.25
Non Currrent Assets Other	0.9	0.86	0.86	0.86	-0.88	-0.8	0.53	0.88	0.88	0.63	0.77	0.12	0.89	0.65	0.89	0.45		0.82	0.65	0.54	0.13	0.85	0.9	0.51	0.14	-0.9
Property Plant And Equipment Gross	0.58	0.64	0.54	0.52	-0.54	-0.76	0.26	0.57	0.57	0.54	0.72	0.16	0.79	0.46	0.57	0.11	0.82		0.7	0.33	0.04	0.78	0.61	0.53	0.08	-0.8
Property Plant And Equipment Net	0.52	0.22	0.34	0.51	-0.48	-0.43	0.33	0.5	0.5	0.11	0.23	0.11	0.5	0.3	0.49	0.05	0.65	0.7		0.6	0.48	0.46	0.33	0.95	0.3	-0.69
Non Current Assets Total	0.59	0.34	0.58	0.57	-0.55	-0.27	0.55	0.54	0.54	0.17	0.03	0.38	0.36	0.61	0.53	0.49	0.54	0.33	0.6		0.83	0.29	0.33	0.6	0.65	-0.6
Other Assets	0.12	-0.15	0.21	0.08	-0.06	-0.09	0.46	0.06	0.06	-0.05	-0.29	0.5	0.08	0.43	0.05	0.12	0.13	0.04	0.48	0.83		0.04	-0.16	0.48	0.76	-0.37
Capital Surpluse	0.7	0.77	0.81	0.59	-0.65	-0.98	0.58	0.69	0.69	0.85	0.94	0.27	0.99	0.7	0.7	0.28	0.85	0.78	0.46	0.29	0.04		0.79	0.21	0.1	-0.86
Other Current Assets	0.92	0.95	0.88	0.89	-0.92	-0.7	0.51	0.93	0.93	0.69	0.83	-0.01	0.82	0.59	0.94	0.63	0.9	0.61	0.33	0.33	-0.16	0.79		0.22	-0.13	-0.68
Property Plant Equipment	0.45	0.09	0.18	0.48	-0.43	-0.17	0.18	0.43	0.43	-0.13	-0.01	-0.02	0.27	0.12	0.42	0.05	0.51	0.53	0.95	0.6	0.48	0.21	0.22		0.26	-0.52
Short Long Term Debt Total	0.11	-0.04	0.11	0.07	-0.05	-0.18	0.07	0.06	0.06	0.13	-0.14	0.35	0.17	0.28	0.05	0.13	0.14	0.08	0.3	0.65	0.76	0.1	-0.13	0.26		-0.46
Other Liab	-0.7	-0.67	-0.73	-0.63	0.65	0.86	-0.45	-0.67	-0.67	-0.6	-0.69	-0.25	-0.9	-0.64	-0.67	-0.25	-0.9	-0.8	-0.69	-0.6	-0.37	-0.86	-0.68	-0.52	-0.46

Click cells to compare fundamentals

Hepion Pharmaceuticals Account Relationship Matchups

Hepion Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	20.6M	48.6M	103.6M	60.2M	18.1M	27.5M
Other Current Liab	851.2K	342.6K	5.2M	5.1M	2.7M	1.8M
Total Current Liabilities	1.6M	4.7M	8.2M	7.9M	5.3M	3.8M
Total Stockholder Equity	15.6M	40.5M	93.0M	49.9M	7.3M	6.9M
Net Debt	(13.1M)	(40.0M)	(91.0M)	(51.1M)	(14.6M)	(15.3M)
Retained Earnings	(83.8M)	(104.1M)	(133.5M)	(175.7M)	(224.6M)	(213.4M)
Accounts Payable	491.6K	3.7M	2.4M	2.7M	2.3M	2.0M
Cash	13.9M	40.7M	91.3M	51.2M	14.8M	22.3M
Cash And Short Term Investments	13.9M	40.7M	91.3M	51.2M	14.8M	24.2M
Common Stock Total Equity	1.7K	375.0	3.2K	7.6K	8.8K	9.2K
Common Stock Shares Outstanding	102.2K	483.9K	3.5M	3.8M	4.0M	4.2M
Liabilities And Stockholders Equity	20.6M	48.6M	103.6M	60.2M	18.1M	27.5M
Non Current Liabilities Total	3.4M	3.5M	2.4M	2.5M	5.5M	4.0M
Other Stockholder Equity	97.7M	142.9M	224.8M	223.9M	230.3M	241.8M
Total Liab	5.0M	8.1M	10.6M	10.4M	10.8M	7.7M
Total Current Assets	14.4M	42.6M	97.5M	56.5M	17.5M	24.0M
Common Stock	25.0	375.0	3.2K	7.6K	482.0	457.9
Non Currrent Assets Other	306.9K	285.1K	583.3K	426.2K	364.2K	228.6K
Property Plant And Equipment Gross	855.1K	108.4K	696.7K	439.2K	621.8K	652.9K
Property Plant And Equipment Net	855.1K	664.9K	456.5K	132.2K	242.4K	289.1K
Non Current Assets Total	6.2M	6.0M	6.1M	3.7M	606.6K	576.2K
Other Assets	3.3M	4.0M	583.3K	426.2K	490.1K	465.6K
Capital Surpluse	76.7M	97.7M	142.9M	223.9M	257.5M	270.4M
Other Current Assets	465.7K	1.9M	6.1M	5.3M	2.7M	2.0M
Property Plant Equipment	855.1K	664.9K	456.5K	81.6K	93.9K	89.2K
Short Long Term Debt Total	807.4K	752.2K	317.0K	53.6K	209.0K	360.0K
Other Liab	2.5M	3.0M	2.3M	2.5M	2.3M	3.2M
Net Tangible Assets	12.6M	36.9M	86.2M	45.0M	51.7M	54.3M
Non Current Liabilities Other	2.4M	2.6M	1.9M	2.1M	1.6M	2.0M
Net Invested Capital	14.5M	39.0M	91.3M	48.2M	5.6M	5.3M
Net Working Capital	13.1M	38.0M	89.2M	48.6M	12.2M	11.6M
Short Term Debt	266.7K	559.7K	533.3K	107.2K	231.8K	359.9K
Capital Stock	1.7M	1.7M	1.7M	1.7M	1.7M	1.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:

How To Invest In Hepion

Details

Is Hepion Stock a good investment?

Details

What is Hepion Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.

You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.40)

Return On Assets

(0.93)

Return On Equity

(1.90)

The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Hepion Ev To Free Cash Flow vs Free Cash Flow Yield Analysis

Ev To Free Cash Flow vs Free Cash Flow Yield

Ev To Free Cash Flow vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Ev To Free Cash Flow

Free Cash Flow Yield

Hepion Pharmaceuticals fundamental ratios Correlations

Hepion Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Hepion Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Capital Surpluse	- 0.98	Retained Earnings